Time to reconsider thromboembolic risk and anticoagulation in transthyretin cardiac amyloidosis?
- PMID: 35919942
- DOI: 10.1002/ejhf.2648
Time to reconsider thromboembolic risk and anticoagulation in transthyretin cardiac amyloidosis?
Comment on
-
Systemic embolism in amyloid transthyretin cardiomyopathy.Eur J Heart Fail. 2022 Aug;24(8):1387-1396. doi: 10.1002/ejhf.2566. Epub 2022 Jul 11. Eur J Heart Fail. 2022. PMID: 35650018 Free PMC article.
References
-
- Porcari A, Merlo M, Rapezzi C, Sinagra G. Transthyretin amyloid cardiomyopathy: an uncharted territory awaiting discovery. Eur J Intern Med. 2020;82:7-15.
-
- Bandera F, Martone R, Chacko L, Ganesananthan S, Gilbertson JA, Ponticos M, et al. Clinical importance of left atrial infiltration in cardiac transthyretin amyloidosis. JACC Cardiovasc Imaging. 2022;15:17-29.
-
- Porcari A, Bussani R, Merlo M, Varrà GG, Pagura L, Rozze D, et al. Incidence and characterization of concealed cardiac amyloidosis among unselected elderly patients undergoing post-mortem examination. Front Cardiovasc Med. 2021;8:1680.
-
- Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007;116:2420-6.
-
- Martinez-Naharro A, Gonzalez-Lopez E, Corovic A, Mirelis JG, Baksi AJ, Moon JC, et al. High prevalence of intracardiac thrombi in cardiac amyloidosis. J Am Coll Cardiol. 2019;73:1733-4.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
